Linagliptin Krka (Linagliptin)

Linagliptin works by selectively inhibiting the dipeptidyl peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels after meals.

The dosage of Linagliptin Krka is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety of linagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Linagliptin Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but differs in its pharmacokinetic profile. It is primarily eliminated via the entero‑hepatic route and does not require dose adjustment in renal impairment, which can be an advantage over some alternatives that need renal dosing modifications.

Linagliptin Krka tablets should be stored below 25 °C in their original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme temperatures or humidity to maintain potency.

Linagliptin Krka is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not split or crush the tablet unless instructed.

Serious but rare risks include pancreatitis, severe allergic reactions such as angioedema, hepatic injury, bullous pemphigoid, and hypoglycaemia when used with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction, or unusual skin lesions.

Linagliptin Krka is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for individuals with severe hepatic impairment, and it should be avoided in pregnancy and lactation unless clearly justified by a physician.